相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A
Wayne L. Furman et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma
Neofit Spasov et al.
CASE REPORTS IN PEDIATRICS (2021)
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) plus Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032
Alice L. Yu et al.
CLINICAL CANCER RESEARCH (2021)
Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma
Jaume Mora et al.
CANCERS (2021)
Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance
Giuseppe Barone et al.
PEDIATRIC DRUGS (2021)
Induction Chemotherapy With an Anti-GD2 Monoclonal Antibody (Dinutuximab) and Cytokines in Children With Newly Diagnosed High-risk Neuroblastoma: A Case Series
Jessica Gartrell et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2021)
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
Ruth Ladenstein et al.
CANCERS (2020)
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group
Rajen Mody et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma
Karoline Ehlert et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
High-dose131I-mIBG as consolidation therapy in pediatric patients with relapsed neuroblastoma and ganglioneuroblastoma: the Japanese experience
Hiroshi Wakabayashi et al.
ANNALS OF NUCLEAR MEDICINE (2020)
Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (sclL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial.
Holger N. Lode et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study
Loredana Amoroso et al.
CANCER RESEARCH AND TREATMENT (2018)
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial
Ruth Ladenstein et al.
LANCET ONCOLOGY (2018)
Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials
Lucas Moreno et al.
PEDIATRIC BLOOD & CANCER (2017)
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting
Julie R. Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Irinotecan-temozolomide with temsirolimus or dinutuximab Crosstafark in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
Rajen Mody et al.
LANCET ONCOLOGY (2017)
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial
Ruth Ladenstein et al.
LANCET ONCOLOGY (2017)
Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study
Shakeel Modak et al.
PEDIATRIC BLOOD & CANCER (2017)
Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials
Wendy B. London et al.
CANCER (2017)
A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma
Sara M. Federico et al.
CLINICAL CANCER RESEARCH (2017)
Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: A European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study
Angela Di Giannatale et al.
EUROPEAN JOURNAL OF CANCER (2014)
Long-Term Results of the Combination of the N7 Induction Chemotherapy and the Busulfan-Melphalan High Dose Chemotherapy
Dominique Valteau-Couanet et al.
PEDIATRIC BLOOD & CANCER (2014)
Ifosfamide, carboplatin, and etoposide for neuroblastoma
Brian H. Kushner et al.
CANCER (2013)
Iodine-123 Metaiodobenzylguanidine Scintigraphy Scoring Allows Prediction of Outcome in Patients With Stage 4 Neuroblastoma: Results of the Cologne Interscore Comparison Study
Boris Decarolis et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma
Kaleem Ashraf et al.
PEDIATRIC BLOOD & CANCER (2013)
Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study
Rochelle Bagatell et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project
Wendy B. London et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Differential Impact of High-Dose Cyclophosphamide, Topotecan, and Vincristine in Clinical Subsets of Patients With Chemoresistant Neuroblastoma
Brian H. Kushner et al.
CANCER (2010)
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
Alice L. Yu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study
Katherine K. Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma.: Results of a phase-II trial
Thorsten Simon et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2007)
Irinotecan plus temozolomide for relapsed or refractory neuroblastoma
Brian H. Kushner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma
A Garaventa et al.
CANCER (2003)
Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A pediatric oncology group phase II study
RL Saylors et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
